• Comirnaty (3 mcg), maroon cap, 0.1 mg/mL concentrate for suspension for injection, infants and children 6 months to 4 years of age (3 micrograms / 0.2 mL dose)
  • Only available for certain infants and children at increased risk of severe COVID-19 (see list below, and in fact sheet and the Starship guidelines for children with complex or multiple health conditions at increased risk of severe COVID-19 for more information)
  • Care must be taken when preparing vaccine to avoid vaccine errors especially in areas giving vaccines to a range of ages.

The incidence of severe or fatal disease in children is significantly lower than in adults. Children at increased risk of more severe disease are predominantly those living with severe immunocompromise or with complex and/or multiple health conditions as described in the Starship Guidelines for COVID-19 in children. These are:

  • Chronic or congenital airway/lung issues including bronchiectasis, cystic fibrosis, BiPAP for OSA (not mild, controlled asthma)
  • Complex congenital heart disease, acquired heart disease or congestive heart failure
  • Diabetes (insulin-dependent)
  • Chronic kidney disease (GFR <15 ml/min/1.73m2)
  • Severe neurodisability including severe neuromuscular conditions
  • Complex genetic, metabolic disease or multiple congenital anomalies including Trisomy 21
  • Primary or acquired immunodeficiency
  • Haematologic malignancy and post-transplant (solid organ or HSCT in last 24 months)
  • On immunosuppressive treatment including chemotherapy, high-dose corticosteroids, biologics or DMARDS.

Resources available


Last updated: 13 February 2023